title: The clinical efficacy and efficiency of a 100-IU starting dose of recombinant follicle stimulating hormone (Puregon) in Korean women undergoing in vitro fertilization and embryo transfer.
abstract: OBJECTIVE
  A prospective, non-comparative study was conducted to evaluate the efficacy and efficiency of a starting dose of 100 IU recombinant follicle stimulating hormone (rhFSH, Puregon) in women undergoing ovarian stimulation prior to in vitro fertilization (IVF).
  
  
  METHODS
  A total of 40 women were down-regulated with gonadotropin releasing hormone agonist (long protocol), then treated with a fixed dose of 100 IU rhFSH for the first 4 days, and the dose of gonadotropin administration was adjusted according to patient's response thereafter. A maximum number of 3 embryos were transferred in 32 patients.
  
  
  RESULTS
  Nine patients were treated with intracytoplasmic sperm injection, and 24 with conventional IVF. The duration of stimulation was 10.8 +/- 1.8 days, serum estradiol concentration on human chorionic gonadotropin day was 1693.0 +/- 1651.2 pg/mL, and 1480 +/- 450 IU rhFSH was used. A mean number of 8.4 +/- 5.7 oocytes were retrieved, 4.9 +/- 4.3 embryos obtained, 2.4 +/- 0.9 embryos transferred, and 3.5 +/- 3.2 embryos cryopreserved. The proportion of mature oocytes was 71.6%, and the fertilization rate was 86.4%. Clinical pregnancy was achieved in 8 patients (25.0%), and all of these pregnancies are ongoing or delivered. There were 3 cases of twin gestations (37.5%). The implantation rate was 13.1% (11/84). There was one case of moderate ovarian hyperstimulation syndrome, however, the patient recovered within 7 days without any complications.
  
  
  CONCLUSIONS
  The starting dose of 100 IU rhFSH has a good safety profile, and is adequate in controlled ovarian hyperstimulation for IVF with a small amount of gonadotropin administered.
authors.affiliation: Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul, Korea. shmoon@plaza.snu.ac.kr
authors.forename: Shin Yong
authors.initials: SY
authors.lastname: Moon
authors.forename: Seok Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Seung Yup
authors.initials: SY
authors.lastname: Ku
authors.forename: Byoung Chul
authors.initials: BC
authors.lastname: Jee
authors.forename: Young Min
authors.initials: YM
authors.lastname: Choi
authors.forename: Jin Yong
authors.initials: JY
authors.lastname: Lee
mesh_terms: D000328:Adult; D010064:Embryo Implantation; D004624:Embryo Transfer; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage*; D043373:Follicle Stimulating Hormone, Human; D006801:Humans; D007723:Korea; D009865:Oocytes; D011247:Pregnancy; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage*; D020554:Sperm Injections, Intracytoplasmic; D020858:Tissue and Organ Harvesting; D016896:Treatment Outcome
chemical_list: D043373:Follicle Stimulating Hormone, Human; D011994:Recombinant Proteins; D004958:Estradiol; D005640:Follicle Stimulating Hormone